China Medical Device QMS

Adapting your medical device QMS (Quality Management System) to meet China’s regulatory requirements is challenging but essential to obtain market approval and ensure ongoing compliance.

The National Medical Products Administration (NMPA), which succeeded the China Food and Drug Administration, is the authority responsible for ensuring that devices and IVDs on the market are fully compliant. To strengthen oversight, the NMPA released the 58th Announcement on December 12th, 2014, focusing on the implementation of Good Supplier Practices (GSP) for medical device distributors. These regulatory requirements apply across the entire product lifecycle to safeguard patient health and product performance.

This means that IVD and Medical Device QMS as well as overall compliance will be checked at various stages throughout their lifecycle.

Medical Device Regulations
Quality Management Requirements

Full Lifecycle QMS Checks

Understanding how these obligations translate into concrete checkpoints is critical, as compliance will 
be verified at multiple stages before and after market entry.

Product Registration – The IVD or medical device QMS will be reviewed as part of the registration submission application process.
Clinical Evaluation & Testing – Higher risk devices may require clinical trials or clinical evaluation reports (CERs) to demonstrate compliance with Chinese safety and performance standards.
Annual Reporting & Renewals – Class II and III medical devices and Class B to D IVDs require annual reports. These must include information on imports and any product recalls or quality management issues. As such, registrations must be renewed every five years, any quality issues will be highlighted for review. High-risk devices are subject to stringent regulations and random inspections by the NMPA to ensure safety and quality standards are met. Thorough due diligence is necessary to comply with these specific requirements.
Importation & Customs Clearance – Devices must include Chinese-language labeling, user instructions, and mandatory symbols following GB standards. This will be checked upon import.
Post-Market Surveillance & Adverse Event Reporting – Once the IVD or device is approved, manufacturers and local agents must establish tracking, monitoring, and reporting systems for IVD or medical device safety and effectiveness.
Factory Inspections – These may be required as part of the registration process or they may be requested as part of the NMPA annual inspection plan. Such inspections, including overseas inspections for overseas manufacturers, will verify that the product is manufactured in compliance with China’s Medical Device Good Manufacturing Practice (GMP) standards.

Quality Management System Requirements

The Quality Management System (QMS) is a cornerstone of medical device and IVD regulations. The NMPA mandates that medical device manufacturers establish and maintain a QMS that not only meets ISO 13485 standards but also incorporates specific Chinese quality management standards. This comprehensive system must cover the entire product lifecycle, from initial design and development to production, quality control, and post-market surveillance.

Medical device manufacturers are required to conduct regular audits and self-inspections to ensure adherence to quality management and identify areas for improvement. The QMS must include detailed procedures for risk management, adverse event reporting, and post-market surveillance, as well as stringent document control and record-keeping practices. By implementing a robust QMS, manufacturers can fully comply with China’s medtech and IVD regulations, maintain high standards of quality and safety, and ultimately protect patient health.

In summary, well-implemented quality management is not just a regulatory requirement but a critical component in the lifecycle of devices, ensuring they meet the highest standards of safety and effectiveness in the Chinese market.

In vitro diagnostic reagents quality management

Our Quality Management Systems Services

We provide end-to-end support to achieve compliance for your Quality Management Systems (QMS) and Good Manufacturing Practices (GMP) to ensure you meet all regulatory requirements.

QMS Gap Analysis & Adaptation

Detailed assessment of your existing ISO 13485 system against NMPA medical device and IVD GMP requirements
Identification of gaps and development of an implementation roadmap
Alignment with China-specific risk management, production controls, and supplier oversight requirements

Document Preparation & Compliance Support

Development and optimization of SOPs (Standard Operating Procedures), work instructions, and quality records to meet NMPA requirements.
Support for establishing and maintaining a Product Technical Requirement (PTR) document, essential for registration and post-market compliance.
Assistance with change control procedures, ensuring smooth implementation of product modifications.

Supplier Qualification & Quality Control

Guidance on supplier qualification and audits to meet China’s GMP and international standards.
Implementation of supplier quality agreements, ensuring main raw materials and components comply with regulatory expectations.
Risk assessment and monitoring of critical suppliers and contract manufacturers.

Production Process Compliance

Implementation of process validation protocols aligned with China’s medical device GMP requirements.
Guidance on establishing corrective and preventive action (CAPA) procedures to meet NMPA expectations.
Support for product release, adverse event monitoring and reporting, maintaining full traceability and product recall systems for post-market obligations.

Chinese GMP Audits

Complying with China’s GMP requirements is mandatory, often requiring on-site audits by the NMPA. Our team helps domestic and overseas manufacturers prepare for and pass these audits with a structured and efficient approach.

GMP Audit Preparation & Mock Inspections

Comprehensive audit readiness assessment to identify gaps before official NMPA inspections.
Mock audits simulating NMPA inspection protocols to ensure preparedness. Conducting a mock overseas inspection helps manufacturers identify and address potential issues before the actual regulatory audit.
Corrective action planning based on common NMPA published findings and industry best practices.
Regular self-inspections are required for enterprises operating Class II and Class III medical devices, with annual self-inspection reports submitted to local drug supervision authorities.

On-Site & Remote NMPA Inspection Support

Assistance during NMPA on-site overseas inspections to ensure smooth regulatory interaction. On-site inspections are crucial for verifying compliance with the Quality Management System (QMS) and regulatory standards.
Support in addressing auditor queries and documentation requests in real time.
Post-audit follow-up to address any non-conformities and regulatory concerns.

GMP Documentation & Process Compliance

Preparation of Chinese GMP-compliant manufacturing process records, including batch records, validation reports, and risk assessments.
Assistance with Good Distribution Practice (GDP) compliance for companies handling medical device logistics and supply chain operations.
Review and optimization of cleanroom, sterilization, and validation processes to meet Chinese regulatory requirements.

Corrective & Preventive Actions (CAPA) Implementation

Development of CAPA systems to resolve deficiencies identified during audits.
Root cause analysis and action planning to ensure continued compliance.
Ongoing monitoring and updates to maintain NMPA GMP compliance.

If you would like more information on China's Medical Device Good Manufacturing Practices and our services please click here.

Useful Articles

View More

Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide

Learn when local testing is required for medical devices and IVDs in Indonesia, which products are affected, and how testing impacts registration requirements.

August 31, 2026
Understanding Local Testing for Medical Devices & IVDs in Indonesia: Requirements & Registration Guide
An Indonesian male medical professional in profile, wearing dark blue scrubs, a blue surgical cap, safety glasses, a white mask, and a blue-tubed stethoscope, presses a button on a dual-monitor medical control panel in a clinical operating setting.

China Medical Device GMP vs ISO 13485: Key Differences Explained

Understand the key differences between China Medical Device GMP and ISO 13485, including requirements for quality management, suppliers, facilities and documentation.

August 26, 2026
China Medical Device GMP vs ISO 13485: Key Differences Explained
Two Chinese medical device technicians, a woman and a man wearing white lab coats, surgical caps, face masks, and protective gloves, stand side by side in a sterile cleanroom environment.

5-Step Guide to Taiwan Medical Device Classification (TFDA)

How to determine medical device classification in Taiwan: the TFDA catalogue, the 16 categories, Class I-III risk levels, and what to do when no item matches.

August 21, 2026
5-Step Guide to Taiwan Medical Device Classification (TFDA)

Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

Learn when medical device and IVD changes in Indonesia require a notification, variation, or new registration, and how to maintain ongoing regulatory compliance.

August 5, 2026
Guide to Indonesia Medical Device Post-Registration Changes: Notification, Variation, or New Registration

How Vietnam Medical Device Registration Works (Timelines, Fees, & AR Strategy)

Gain an overview of the medical device registration process in Vietnam with timelines, fees, and Authorized Representative requirements.

August 4, 2026
How Vietnam Medical Device Registration Works (Timelines, Fees, & AR Strategy)

Understanding the ASEAN Medical Device Market: Comparing 6 Strategic Markets

Explore the medical device market opportunities, regulations, and registration pathways across Malaysia, Singapore, Vietnam, and other key ASEAN countries.

August 4, 2026
Understanding the ASEAN Medical Device Market: Comparing 6 Strategic Markets
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

Learn more

Latest Insights

View More

Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

Circular No. 2/2026 revises prohibited, restricted, colorant, and preservative requirements for cosmetics marketed in Malaysia.

August 20, 2026
Malaysia NPRA Updates Cosmetic Ingredient Requirements Under the ASEAN Cosmetic Directive

China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?

Brands must audit ingredients, suppliers and packaging before January 2028 to ensure compliance with GB 7916-2026.

August 18, 2026
China Overhauls Cosmetic Safety Rules with GB 7916-2026: Is Your Brand Ready?
Scientist in clean modern room inspects cosmetics.

China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Companies can benefit from expanded toxicology data exemptions, simplified cosmetics registration procedures, and more efficient compliance pathways

August 18, 2026
China Expands Animal Testing Data Exemptions in Major Cosmetics Registration and Filing Reform

Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

As of July 1, 2026, Taiwan has completed its cosmetic GMP rollout, extending mandatory ISO 22716-based manufacturing standards to nearly all cosmetic factories

August 18, 2026
Taiwan Extends Cosmetic GMP Requirements to Nearly All Manufacturing Sites

China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed

New NCI rules reduce administrative burden, streamline dossiers, and expand opportunities to reuse existing safety data.

August 18, 2026
China Updates New Cosmetic Ingredient Registration Rules: Several Higher-Risk Ingredient Categories Removed
This stock photo features a close-up, high-angle shot focusing on a skincare product arrangement set against a light-colored, wood-grain surface.

NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria

Review China's new draft standards for cosmetic cheilitis and contact urticaria before the August 15, 2026, consultation deadline.

August 18, 2026
NMPA Opens Consultation on Two Draft Cosmetic Adverse Reaction Standards: Cosmetic Cheilitis & Cosmetic Contact Urticaria
Previous
Previous

Get in Touch with Our Life Sciences Team

And discover how we can support you in adapting your quality management system for your medical device or IVD in China.

Request Proposal